Purpose: To evaluate the effect of glucocorticoid (triamcinolone acetonide injectable suspension) pretreatment on corneal neovascularization, lymphangiogenesis, and inflammation in a murine penetrating keratoplasty (PK) and corneal suture model. FIGURE 4. A and B, In the corneal suture model, groups A and C showed significantly less neovascularization and lymphangiogenesis compared with group B (P , 0.05). There was no significant difference of neovascularization and lymphangiogenesis between groups A and C (P . 0.05). C, Representative pictures of groups A, B, and C. Upper row, fluorescent microscopic picture of CD31 staining (green) in flat mount of whole cornea; middle row, fluorescent microscopic picture of LYVE-1 staining (red) in flat mount of whole cornea; bottom row, confocal microscopic picture of CD11b staining cells (green) around suture area.
Methods: For the PK model, BALB/c mice were used as recipients and C57BL/6 mice were used as donors. A group pretreated with subconjunctival glucocorticoid and a combination of post-subconjunctival and topical glucocorticoids (group I) was compared with two groups that did not receive glucocorticoid pretreatment [one group received a combination of subconjunctival and topical glucocorticoids postoperatively (group II) and the other group received only topical glucocorticoid treatment postoperatively (group III)]. All groups were treated with subconjunctival glucocorticoid on the day of surgery. For the corneal suture model, BALB/c mice were used. A group receiving only pre-suture glucocorticoid treatment (group A) and a group receiving only post-suture glucocorticoid treatment (group C) were compared with a control group that did not receive glucocorticoid therapy (group B). The degree of neovascularization, lymphangiogenesis, and inflammatory infiltration was compared in each of these models.
Results: In the PK model, the group receiving glucocorticoid pretreatment (group I) showed less neovascularization compared with the posttreatment-only groups (group II, P = 0.043; group III, P = 0.020) and less lymphangiogenesis compared with group III (P = 0.005). In the corneal suture model, the glucocorticoid pretreatment group showed a similar level of neovascularization, lymphangiogenesis, and inflammatory infiltration as the posttreatment-only groups (P . 0.05).
Conclusions: Glucocorticoid pretreatment before PK decreases neovascularization and lymphangiogenesis compared with posttransplant glucocorticoid treatment alone.
Key Words: penetrating keratoplasty, glucocorticoid pretreatment, angiogenesis, triamcinolone acetonide (Cornea 2012;31:1468-1475) P enetrating keratoplasty (PK) is one of the most successful organ transplant procedures worldwide with 2-year survival rates as high as 90% in uncomplicated cases. [1] [2] [3] Conversely, even with current immunosuppression techniques, corneal graft rejection rates in high-risk patients can exceed 70%. 4 Key risk factors for graft rejection include active inflammation and corneal vascularization. 5, 6 Corticosteroids are the current standard of care for prevention of graft rejection after PK because of their strong antiinflammatory effects. 1, [7] [8] [9] [10] [11] The antiinflammatory effects of corticosteroids occur through the inhibition of chemotaxis and phagocytosis and by blocking the synthesis of prostaglandins through the phospholipase A2 pathway. 7, 8, 12 They also inhibit vascularization and have immunosuppressive action by reducing the number of circulating T lymphocytes. The mechanisms by which glucocorticoids inhibit angiogenesis include direct effects on vascular endothelial cells and indirect effects on other cells, resulting in the inhibition of migration and activation of macrophages, mast cells, and other cell types that release agents contributing to angiogenesis. [13] [14] [15] [16] [17] Glucocorticoids also exert an antilymphangiogenic effect. 13, 18, 19 Corneal transplantation has a 2-year success rate of over 90% for initial grafts into an avascular cornea. 1, 3 However, in patients with high-risk characteristics such as a vascularized corneal recipient bed, graft failure rates are between 60% and 90%. 1, 2, 20, 21 Vascularized and inflamed corneal tissue provides a conduit for both the blood and lymphatic systems to bring immune cells to and from the cornea, contributing to subsequent immunologic graft rejection. 1, 2, 10, [20] [21] [22] As a result, the graft rejection cascade can be initiated or accelerated. Perioperative suppression of neovascularization, lymphangiogenesis, and inflammation could be a key factor in improving the outcomes of ocular surgeries, including keratoplasty and wound healing. 19, 20 Blood and lymphatic vessels grow into the cornea as early as the second day after an angiogenic inflammatory insult. 14, 18, 19, 23 In murine PK models, lymphatic vessels can reach the graft-host interface within 6 days of surgery. 19, 24 As a result, starting antiinflammatory treatment after the insult occurs may not be sufficient to prevent or slow angiogenesis. Therefore, starting antiinflammatory therapy before the insult may decrease angiogenesis and improve outcomes.
Currently, the most common immunosuppressive regimen is the combination of subconjunctival glucocorticoid injection at the time of surgery followed by continued topical glucocorticoid application. 9, 10 Although it is generally accepted that glucocorticoids exert a protective effect against corneal graft rejection at the time of and after surgery, their potential use before PK has not been thoroughly examined. The aim of this study was to evaluate the impact of glucocorticoid pretreatment on corneal neovascularization, lymphangiogenesis, and inflammation in murine PK and corneal suture models.
MATERIALS AND METHODS
All experiments were performed in accordance with the regulations of Association for Research in Vision and Ophthalmology and were approved by the Institutional Animal Care and Use Committee of the University of Utah.
PK Model Orthotopic Corneal Transplantation
Penetrating corneal transplantation was done using BALB/c mice as recipients (12 mice in group I, 13 mice in group II, and 10 mice in group III) and C57BL/6 mice as donors (The Jackson Laboratory, JAX Mice and Services, Bar Harbor, ME). All mice were male and 8 to 12 weeks old. Mice were anesthetized by intramuscular injection with ketamine (100 mg/kg) and xylazine (20 mg/kg). The donor cornea was marked with a 2-mm trephine, the anterior chamber was penetrated using a knife (ClearCut, Alcon, Inc) and the cornea was cut with Vannas scissors and placed in balanced salt solution (Alcon Laboratories, Inc, Fort Worth). The recipient mouse was anesthetized as described previously. To dilate and anesthetize the pupil, 1% tropicamide ophthalmic solution and 0.5% proparacaine ophthalmic solution were used. The recipient's right cornea was marked with a 1.5-mm trephine and removed by the same method as the donor cornea. The donor graft was sutured into the recipient bed using 6 to 8 interrupted sutures (11-0 nylon, CS160-6; Ethicon, Inc). After the transplantation, the eye was covered with 0.5% erythromycin ophthalmic ointment and the lid was sutured with 8-0 coated vicryl sutures (BV130-5, Ethicon, Inc). Sutures were removed after 1 week.
Glucocorticoid Treatment
Kenalog-40 injection (triamcinolone acetonide injectable suspension, unique selling proposition, 40 mg/mL) was used as the glucocorticoid pretreatment in this study. Figure 1 details the timing of glucocorticoid application in the PK model. The long-acting glucocorticoid (triamcinolone) was given by subconjunctival injection (10 mL). In group I, glucocorticoid injections were given twice a week for 3 weeks before PK, on the day of PK, and weekly for 4 weeks after PK. Topical glucocorticoid drops (2 mL of triamcinolone acetonide injectable suspension, 40 mg/mL) were then given twice a week during weeks 4 to 8 (post-PK). In group II, subconjunctival glucocorticoid injection was started on the day of PK and given weekly through week 4 after PK, followed by topical glucocorticoid drops twice weekly during weeks 4 to 8. In group III, glucocorticoid subconjunctival injection was given on the day of PK followed by topical glucocorticoid drops twice a week for 8 weeks.
Clinical Evaluation of Rejection
The mice were examined every week using an operating microscope (SZX7; Olympus, Tokyo, Japan). Corneal opacity was graded (0-5) to determine graft rejection. 25 Opacity of grade 3 or higher was considered to be a graft rejection. Mice with severe inflammation and hemorrhage were excluded from the study. Mice with significant cataract were excluded from opacity grading but were included in flat mounting for the calculation of angiogenesis and lymphangiogenesis.
Analysis of Angiogenesis and Lymphangiogenesis
After planned treatment injections and observations, mice eyes were harvested (9 corneas in group I, 11 corneas in group II, and 9 corneas in group III). The cornea was trimmed of remaining limbus and iris. Immunohistochemical staining for vascular and lymphatic endothelial cells was performed on corneal flat mounts. Corneas were dissected, rinsed in phosphate-buffered saline (PBS) for 30 minutes, and fixed in 100% acetone (Sigma) for 20 minutes. After washing in PBS with 0.1% Tween 20, nonspecific binding was blocked with 3% bovine serum albumin (BSA)/PBS for 3 nights at 4°C. Incubation with fluorescein isothiocyanate-conjugated monoclonal anti-mouse CD31 antibody (558738; BD Pharmingen) at a dilution of 1:500 and rabbit anti-LYVE-1 (ab 14917; Abcam Inc, Cambridge, MA) at a dilution of 1:200 in 3% BSA/PBS at 4°C overnight was followed by 1:1000 goat anti-rabbit antibody-Alexa Fluor 546 (A11071; Invitrogen Corporation, Carlsbad, CA) for 1 hour, and subsequent washes in PBST at room temperature. Corneas were mounted with the antifading agent Gelmount (Biomeda, San Francisco, CA). After immunochemical staining and flat mounting, images of the corneal vasculature were captured using a fluorescent microscope (Carl Zeiss MicroImaging, Inc, Thornwood, NY). The neovascularization and lymphangiogenesis were quantified by setting a threshold level of fluorescence above which only vessels were captured and processed using ImageJ (National Institutes of Health). The total corneal area was outlined using the innermost vessel of the limbal (rim of the cornea) arcade as the border and the graft area was outlined using the scar line between the recipient and donor graft. The total area of neovascularization and lymphangiogenesis was normalized to the total corneal area. The graft neovascularization and lymphangiogenesis were normalized to the graft area. The 3 groups were compared by graft survival, neovascularization (NV) (total corneal NV = total NV area/total corneal area), graft NV (graft NV area/graft area), lymphangiogenesis (LY) (total corneal LY = total LY area/total corneal area), and graft LY (graft LY area/graft area).
Intraocular Pressure
Intraocular pressure (IOP) was monitored by averaging 5 tonometer (TonoLab tv 02; Icare, Espoo, Finland) measurements for each eye. The IOP of eyes pretreated with glucocorticoids (N = 12) and the fellow eyes of group I (N = 12) were compared before PK on the day of surgery. The IOPs of group II (N = 13) were measured before PK on the day of surgery.
Corneal Suture Model Animals
BALB/c mice (The Jackson Laboratory, JAX Mice and Services) aged 8 to 10 weeks were used. Before the corneal suture was placed, mice were anesthetized with intramuscular tribromoethanol (Avertin) and 0.5% proparacaine ophthalmic solution. Two corneal sutures were placed with 11-0 nylon between the corneal center and the limbus at the 12-and 6-o'clock positions. After suture placement, 0.5% topical erythromycin ointment was applied to the cornea. Figure 1 shows the schedule of glucocorticoid application in the corneal suture model. In group A, subconjunctival glucocorticoid was injected twice during the week before suture placement (on days 7 and 4 before suture placement), then corneal sutures were placed (day 0) and corneas were harvested 1 week after suture placement (day 7). In group B, corneal sutures were placed without any pretreatment on day 0 and corneas were harvested 1 week after suture placement (day 7). In group C, corneal sutures were placed (day 0), after which we injected subconjunctival glucocorticoid on days 2 and 4 and harvested the cornea 1 week after suture placement (day 7).
Preoperative and Postoperative Injection of Glucocorticoids

Analysis of Angiogenesis, Lymphangiogenesis, and Inflammatory Infiltration
After planned injections and observations, the eyes were harvested (6 corneas in group A, 6 corneas in group B, and 5 corneas in group C). The cornea was trimmed of the remaining limbus and iris. Immunohistochemical staining for vascular endothelial cells, lymphatic endothelial cells, and monocyte and macrophage was performed as previously described. Image analysis of fluorescent microscopic picture was the same as above (in the PK model).
To quantify the volume of inflammatory infiltration, we used a confocal microscope (Olympus FluoView FV1000; Olympus). A total of 12 suture sites in group A, 12 suture sites in group B, and 10 suture sites in group C were quantified. Horizontal sections (objective magnification, ·10) were obtained from the surface of the suture to the deepest focal plane of neovascularized area around the suture in 5-mm steps. A total of 22 to 30 slices of 2-dimensional horizontal section images were stacked to form a 3-dimensional volume of each suture area. The number of pixels stained with CD11b was used to calculate the volume. Scaling factors (mm per pixel) for x, y, and z dimensions were 1.242, 1.242, and 5, respectively.
Statistical Analysis
For statistical analysis, we used SPSS 11.5 for Windows. To compare graft survival, we used the Kaplan-Meier analysis and log-rank test. To compare neovascularization, lymphangiogenesis, inflammatory infiltration, and IOP, unpaired 2-tailed t tests and Mann-Whitney U tests were used.
RESULTS
PK Model Graft Survival
Group I (75.0%) showed a trend toward increased survival compared with groups II (51.9%) or III (55.5%) based on opacity grading, but this difference did not reach statistical significance (Fig. 2) (P = 0.408 and 0.560, respectively).
Neovascularization
For total corneal neovascularization, group I (mean ± SEM; 0.062 ± 0.008, N = 9) demonstrated significantly less total neovascularization than group II (0.112 ± 0.019, P = 0.043, N = 11) or group III (0.139 ± 0.028, P = 0.020, N = 9). The difference in total neovascularization between groups I and II is probably because of the addition of glucocorticoid pretreatment before PK in group I. Combination glucocorticoid treatment before and after PK has the potential to decrease corneal neovascularization compared with only postoperative treatment. The difference between groups I and III was larger than that for groups I and II, probably because of group II receiving additional postoperative subconjunctival glucocorticoid therapy after corneal transplantation. There was no significant difference in graft neovascularization between the groups (Fig. 3 ).
Lymphangiogenesis
Group I (0.033 ± 0.008) showed significantly less total lymphangiogenesis compared with group III (0.098 ± 0.018, P = 0.005). Group I (0.035 ± 0.008) also showed significantly less graft lymphangiogenesis compared with group III (0.166 ± 0.050, P = 0.020). Figure 3 shows comparisons of lymphangiogenesis and their representative pictures. Group II (0.040 ± 0.006) showed significantly less total lymphangiogenesis than group III (0.098 ± 0.018, P = 0.007). Pretreatment with subconjunctival glucocorticoids suppressed lymphangiogenesis. Furthermore, when comparing the 2 posttreatment groups, combined subconjunctival injection posttreatment was more effective in decreasing lymphangiogenesis than topical posttreatment alone.
Intraocular Pressure
Before PK, there was no significant difference in IOP between the PK scheduled eye (mean ± SEM, mm Hg; 9.90 ± 0.67) and the fellow eye of group I (10.30 ± 0.74) or the PK scheduled eye of groups I and II (9.61 ± 0.41). In our study, glucocorticoid pretreatment twice a week for 3 weeks before PK (total 2.4 mg of triamcinolone acetonide per eye) did not increase IOP compared with eyes not receiving glucocorticoid treatment. Figure 4 presents the result from the corneal suture model. Groups A (0.018 ± 0.007) and C (0.008 ± 0.002) FIGURE 2. A, Kaplan-Meier survival graph of groups I, II, and III in the PK model. Group I showed improved graft survival compared with groups II and III, but this did not reach statistical significance (P = 0.408 and 0.560). B, Representative pictures of groups I, II, and III.
Corneal Suture Model Neovascularization and Lymphangiogenesis
showed significantly less neovascularization compared with group B (0.117 ± 0.022, P = 0.002 and 0.004, respectively). Groups A (0.009 ± 0.002) and C (0.010 ± 0.002) showed significantly less lymphangiogenesis than group B (0.045 ± 0.008) (P = 0.004 and 0.009, respectively). There was no significant difference in neovascularization or lymphangiogenesis between groups A and C. Both glucocorticoid pretreatment and posttreatment groups showed less neovascularization and lymphangiogenesis than the group without glucocorticoid treatment. We found that glucocorticoid pretreatment showed a similar effect to posttreatment in decreasing neovascularization and lymphangiogenesis. Figure 4 shows the comparison of volume of CD11b + cell infiltration of each suture area and their representative pictures. Groups A (mm 3 ; 0.266 · 10 7 ± 0.115 · 10 7 ) and C (0.172 · 10 7 ± 0.049 · 10 7 ) demonstrated significantly less infiltration of CD11b + cells than group B (0.680 · 10 7 ± 0.191 · 10 7 ) (P = 0.028 and 0.030, respectively). There was no difference in infiltration of CD11b + cells between groups A and C. Both glucocorticoid pretreatment and posttreatment groups showed less inflammatory infiltration than groups without glucocorticoid treatment. We found that FIGURE 3 . A and B, In the PK model, group I showed significantly less total neovascularization compared with groups II and III (P = 0.043 and 0.020, respectively) and less total lymphangiogenesis (P= 0.005) and less graft lymphangiogenesis (P = 0.020) compared with group III. C, Representative pictures of groups I, II, and III. Upper row, CD31 staining; lower row, LYVE-1 staining. glucocorticoid pretreatment showed a similar effect to posttreatment in decreasing inflammatory infiltration.
Volume of Monocyte/Macrophage Infiltration in Confocal Microscope
DISCUSSION
Corneal transplantation often represents one of the last options available for restoring sight for patients with blindness due to corneal opacification. Although several decades have passed since the initial development of corneal transplantation, the mainstay of treatment to increase transplant survival continues to be glucocorticoid therapy. [7] [8] [9] [10] [11] 22, 26 In high-risk PK, other immunosuppressive agents have been used but are typically combined with glucocorticoid treatment. 9, 11 We hypothesized that fostering a good milieu in the recipient bed by suppressing inflammation and vascularization through steroid pretreatment would improve corneal engraftment through decreased neovascularization, lymphangiogenesis, and inflammation and result in improved graft survival. Although our PK model results showed a decrease in neovascularization and lymphangiogenesis, unfortunately there was no increase in graft survival compared with current treatment regimens.
VEGF gene expression that is induced within 24 hours after corneal injury is stimulated by proinflammatory cytokines. 27, 28 These cytokines are expressed as early as 1 hour after corneal injury. 28 As glucocorticoid treatment can suppress proinflammatory cytokines and inhibit cell chemotaxis, the maximum concentration of glucocorticoid in the cornea should be maintained during the early wound healing period.
As time is required for the glucocorticoid to distribute in the cornea and anterior chamber, pretreatment with the glucocorticoid can increase the concentration at the time of corneal injury to allow for the maximal antiinflammatory effect. Therefore, starting glucocorticoid treatment after the insult may not be optimal and beginning treatment before the insult may be beneficial. Published reports reviewing glucocorticoid treatments found that they are most effective in angiogenesis suppression when they are applied before or immediately after the corneal injury. [29] [30] [31] Blood and lymphatic vessels can grow into the cornea as early as day 2 after an angiogenic inflammatory insult. 14, 18, 19, 23 In murine PK, lymphatic vessels can reach the graft-host interface within 6 days of surgery. 19, 32 When glucocorticoids are applied by subconjunctival injection at the time of PK, the peak concentration in the anterior chamber via transcorneal delivery occurs after the expression of the cytokines induced by the injury. 29, 31, 33 Thus, maintaining the highest concentration of antiinflammatory treatment at the time of injury is expected to prevent or slow cytokine expression. As a result, starting antiangiogenic and antiinflammatory treatment after the insult may not be sufficient and starting treatment before the insult may be required to minimize angiogenesis.
Another issue is that angiogenesis and lymphangiogenesis peak after a stimulus and then stabilize or regress as the lesion heals and the stimulus is removed 18, 23 If the stimulus were transient and easily dissipated, such as a thermal corneal injury, early perioperative treatment for preventing neovascularziation and lymphangiogenesis near the time of stimulus could be effective. But if the stimulus were to be prolonged, sustained treatment would be more important than early perioperative treatment. Keratoplasty can be a transient angiogenic stimulus or prolonged angiogenic stimulus depending on the individual risk factors. Blood vessels and lymphatic vessels reaching the graft are essential for delivery of antigen-presenting cells and alloreactive T lymphocytes to the graft. 1, 3 If sensitized T cells do not occur until 14 to 21 days after grafting, they must compete with the regulatory T cells of anterior chamber-associated immune deviation, which begin to emerge at that time. 3, 24, 25, 34 Therefore, in PK if the growth of afferent rim (lymphatics) can be slowed in the early perioperative period, keratoplasty could be a transient stimulus under the control of anterior chamber-associated immune deviation. Thus, if we can reduce or shorten the stimulus causing antigen presentation to the immune system, then there would not be additional stimulus to activate the efferent arm, thereby limiting the immune reaction.
Because glucocorticoid pretreatment showed a trend toward increased graft survival (which did not reach statistical significance) in this trial, it suggests that there may be other factors that contribute to graft survival beyond neovascularization and lymphangiogenesis. However, optimizing the pretreatment regimen by taking into account factors such as glucocorticoid duration of action and potency could yield improved survival. Therefore, pretreatment using longer acting and increased potency glucocorticoids may improve PK outcomes and should be investigated. 7, 13, 35 It is widely accepted that topical glucocorticoid treatment can protect against immunologic graft rejections in normal-risk PK. In our study, group II (group receiving a combination of subconjunctival and topical glucocorticoids postoperatively) showed less total lymphangiogenesis than group III (group receiving only topical glucocorticoids treatment postoperatively; P = 0.007). As a result, the mode of delivery should be a consideration when designing treatment regimens aimed at reducing neovascularization and lymphangiogensis, especially in high-risk keratoplasty where topical glucocorticoid treatment may not be enough to protect against graft rejection. 1, 2, 7, 21, 35, 36 One consideration that must be taken into account with any glucocorticoid treatment is the potential for an elevation of IOP. 7, 37 Although this was a concern for our model, our study found no increase in IOP in the eyes pretreated with glucocorticoids. This suggests that the potential benefits of using glucocorticoids before an angiogenic stimulus may outweigh the risk of increased IOP and should be further investigated. Cataractogenesis is another known risk associated with glucocorticoid use. Unlike groups II and III that used glucocorticoids only after the postoperative period (for a total of 8 weeks), group I was exposed to glucocorticoid both preoperatively and postoperatively (for a total of 11 weeks) and had cataract development in 2 eyes. This is likely related to the increased glucocorticoid exposure of group I. Another risk associated with glucocorticoid use is eruption of a nascent corneal infection, especially with long-term use. We did not find any signs of corneal infection during the course of our study, although this may, in part, be because of using 5% erythromycin ophthalmic ointment at the time of surgery.
One limitation of our study is that we did not compare the effectiveness of topically administered glucocorticoid pretreatment with subconjunctival glucocorticoid pretreatment, although based on published findings we would not expect the topically administered pretreatment to be more effective than subconjunctival delivery. 38, 39 A second limitation is that we focused on the clinical markers of efficacy such as corneal opacification. Further research could use biochemical markers such as CD11b or F4/80 to determine the effectiveness of glucocorticoid pretreatment of decreased immune reaction.
In conclusion, glucocorticoid therapy has been the standard antiinflammatory and antiangiogenic treatment for diseases associated with corneal neovascularization and lymphangiogenesis, including corneal transplantation. This study found that glucocorticoid delivery before an angiogenic stimulus such as PK or a corneal suture is effective in reducing angiogenesis, lymphangiogenesis, and inflammatory infiltration. Therefore, glucocorticoid pretreatment should be considered in the optimization of antiangiogenesis, antilymphangiogenesis, and transplant survival protocols.
